The importance of patient‐centred drug development for amyotrophic lateral sclerosis

Abstract

Neuropathology and Applied NeurobiologyVolume 49, Issue 6 e12944 LETTER TO THE EDITOR The importance of patient-centred drug development for amyotrophic lateral sclerosis Matthew C. Kiernan, Matthew C. Kiernan Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, AustraliaSearch for more papers by this authorGlenda M. Halliday, Glenda M. Halliday orcid.org/0000-0003-0422-8398 Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Sydney, New South Wales, AustraliaSearch for more papers by this authorDominic B. Rowe, Dominic B. Rowe Macquarie University Centre for Motor Neuron Disease Research, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, AustraliaSearch for more papers by this authorRachel H. Tan, Corresponding Author Rachel H. Tan [email protected] orcid.org/0000-0002-0385-4090 Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia Correspondence Rachel H. Tan, Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, Sydney, NSW 2050, Australia. Email: [email protected]Search for more papers by this author Matthew C. Kiernan, Matthew C. Kiernan Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, AustraliaSearch for more papers by this authorGlenda M. Halliday, Glenda M. Halliday orcid.org/0000-0003-0422-8398 Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Sydney, New South Wales, AustraliaSearch for more papers by this authorDominic B. Rowe, Dominic B. Rowe Macquarie University Centre for Motor Neuron Disease Research, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, AustraliaSearch for more papers by this authorRachel H. Tan, Corresponding Author Rachel H. Tan [email protected] orcid.org/0000-0002-0385-4090 Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia Correspondence Rachel H. Tan, Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, Sydney, NSW 2050, Australia. Email: [email protected]Search for more papers by this author First published: 07 November 2023 https://doi.org/10.1111/nan.12944Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Yang Y, Rowe D, McCann H, et al. Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS. Neuropathol Appl Neurobiol. 2023; 49(4):e12919. doi:10.1111/nan.12919 2Liddell J, Hilton J, Crouch P. CuII(atsm) significantly decreases microglial reactivity in patients with sporadic ALS. Neuropathol Appl Neurobiol. 2023; 49(5):e12938. doi:10.1111/nan.12938 3Ashford BA, Boche D, Cooper-Knock J, Heath PR, Simpson JE, Highley JR. Review: microglia in motor neuron disease. Neuropathol Appl Neurobiol. 2021; 47(2): 179-197. doi:10.1111/nan.12640 4Brettschneider J, Toledo JB, Van Deerlin VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012; 7(6):e39216. doi:10.1371/journal.pone.0039216 5Pinkerton M, Lourenco G, Pacheco MT, Halliday GM, Kiernan MC, Tan RH. Survival in sporadic ALS is associated with lower p62 burden in the spinal cord. J Neuropathol Exp Neurol. 2023; 82(9): 769-773. doi:10.1093/jnen/nlad051 Volume49, Issue6December 2023e12944 ReferencesRelatedInformation